Open access
Aug 2026
Indirect comparison of mRNA-1010 versus enhanced influenza vaccines in adults aged 65 years and older during the 2024-2025 US influenza season.
MRNA-1010, a new mRNA-based influenza vaccine, was shown to be comparable to currently licensed EVs among older adults ≥65 years against medically attended influenza outcomes, and provides an additional comparable option to existing EVs to help further reduce severe influenza disease burden.
K. Joshi, A. Situ, D. Mehta et al.
· Journal of Medical Economics · 1 citation